Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucrictibant for prophylactic and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency
2025-522051-26-00Phase 3Authorised
- Sponsor
- Pharvaris
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of deucrictibant in acquired C1 esterase inhibitor deficiency (AAE) (5 arms), sponsored by Pharvaris. Primary endpoints: Time-normalized number of investigator-confirmed attacks, Time to symptom relief by PGI-C and 2 more. Planned start Apr 2026; status: authorised.
02
Drugs
deucrictibant
03
Conditions
acquired C1 esterase inhibitor deficiency (AAE)
Beyond the preview
Go deeper on 2025-522051-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522051-26-00.